NovaBridge Biosciences (NBP) Liabilities and Shareholders Equity (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $260.5 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $260.5 million, up 22.49% year-over-year; the trailing twelve-month figure through Dec 2025 was $953.6 million (up 36.38% YoY), and the FY2025 annual result was $260.5 million, up 22.49% from the prior year.
• Liabilities and Shareholders Equity fell to $260.5 million in Q4 2025 per NBP's latest filing, from $277.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $952.2 million in Q2 2021 and troughed at $206.7 million in Q2 2025.
• A 5-year average of $436.5 million and a median of $277.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity surged 228.37% in 2021, then tumbled 49.37% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $876.1 million in 2021, then tumbled by 34.62% to $572.8 million in 2022, then sank by 36.64% to $362.9 million in 2023, then slumped by 41.4% to $212.7 million in 2024, then advanced by 22.49% to $260.5 million in 2025.
• Business Quant data shows NBP's Liabilities and Shareholders Equity at $260.5 million in Q4 2025, $277.4 million in Q3 2025, and $206.7 million in Q2 2025.